Method To Prevent Biofilm Formation in Various Clinical Settings (Contact Lenses, Wounds, Cystic Fibrosis, etc.)
Tech ID: 04-08
New Method Attacks Bacterial Infections of Contact Lenses
Researchers at National Jewish Health have determined that actin originating from necrotized human neutrophils serve as a biological matrix in the formation of microbial biofilms in the airways of cystic fibrosis (CF) patients. Since biofilm formation allows for the survival of microbial organisms in the airways of CF patients and is also associated with increased morbidity and mortality, targeting actin and/or neutrophils could be the basis for the development of a potential therapy for CF.
Targeted therapy for preventing or reducing biofilm formation in cystic fibrosis, infectious kidney stones, cystitis, dental caries, chronic otitis media, bacterial endocarditis, osteomyelitis, wounds, and acne.
Prevention of microbial biofilm development on contact lenses, orthopedic implants, stents, catheters and other medical devices.
An assay to test compounds for their ability to prevent/reduce biofilm formation by assessing the ability of microbial organizations to bind actin.
Advantages of Invention
This therapy, focused on biofilm prevention or degradation, is particularly applicable for early stage CF in young patients when antimicrobial agents are only partially effective at best.
State of Development
Our scientists have shown the following in vitro:
Further R&D Required
Using the state grant to identify the most effective charged poly(amino acids) at disrupting biofilms and testing such compounds on infected contact lenses, and in animal models of eye and skin infections.
Walker, T. S., K. L. Tomlin, G. S. Worthen, K. R. Poch, J. G. Lieber, M. T. Saavedra, M. B. Fessler, K. C. Malcolm, M. L. Vasil, and J. A. Nick. "Enhanced Pseudomonas Aeruginosa Biofilm Development Mediated by Human Neutrophils." Infection and Immunity 73.6 (2005): 3693-701. Print. PMID: 15908399.
Parks, Q. M., R. L. Young, K. R. Poch, K. C. Malcolm, M. L. Vasil, and J. A. Nick. "Neutrophil Enhancement of Pseudomonas Aeruginosa Biofilm Development: Human F-actin and DNA as Targets for Therapy." Journal of Medical Microbiology 58.4 (2009): 492-502. Print. PMCID: PMC2677169.
Robertson, D. M., Q. M. Parks, R. L. Young, J. Kret, K. R. Poch, K. C. Malcolm, D. P. Nichols, M. Nichols, M. Zhu, H. D. Cavanagh, and J. A. Nick. "Disruption of Contact Lens-Associated Pseudomonas Aeruginosa Biofilms Formed in the Presence of Neutrophils." Investigative Ophthalmology & Visual Science 52.5 (2011): 2844-850. Print. PMID: 21245396.
J.A. Nick, MD, T.S. Walker, G.S. Worthen, MD, Quinn Parks, PhD
U.S. Patents #8,753,662 and #8,901,167. Additional patents pending.
Published U.S. Patent Application #20060030539; Published U.S. Patent Application #20080207556; Published U.S. Patent Application #20080199509; International Patent Application #WO2006/017816. An additional patent application pending.
This technology is available for licensing.
For Further Information, Contact:
Emmanuel Hilaire, PhD
Technology Transfer Office
National Jewish Health
1400 Jackson Street, Room M206b
Denver, CO 80206